Preferentially Expressed Antigen in Melanoma (PRAME) as a diagnostic and predictive marker in melanocytic tumors: An updated narrative review

Simple item page
dc.contributor.authorRosario Caltabiano
dc.contributor.authorMagda Zanelli
dc.contributor.authorAndrea Palicelli
dc.contributor.authorMaurizio Zizzo
dc.contributor.authorIoannis Boutas
dc.contributor.authorNektarios Koufopoulos
dc.contributor.authorGiuseppe Broggi
dc.contributor.authorSerena Salzano
dc.contributor.departmentBiología Celular e Histología
dc.date.accessioned2025-11-10T11:41:54Z
dc.date.available2025-11-10T11:41:54Z
dc.date.issued2025
dc.description.abstractMelanocytic neoplasms range from benign nevi to malignant melanomas, and accurate differen-tiation between these lesions is crucial for effective treatment. Among the various immuno-histochemical markers available, PRAME (Preferentially Expressed Antigen in Melanoma) has emerged as a significant diagnostic tool in the evaluation of melanocytic lesions due to its high sensitivity and specificity, particularly in distinguishing malignant melanomas from benign nevi. PRAME is strongly expressed in malignant melanomas, including cutaneous, uveal, and mucosal variants, while its expression is minimal or absent in benign and dysplastic nevi. Its utility extends to identifying metastases, especially in difficult-to-diagnose cases such as metastatic melanoma, where it aids in differentiating melanoma from other malignancies. Additionally, the presence of PRAME is associated with poor prognosis, as higher expression levels correlate with increased metastatic risk. Despite its effectiveness, the use of PRAME in immunohistochemistry is not without limitations. It is not exclusive to melanoma, as its expression can be seen in some non-melanocytic tumors, which may reduce its specificity in certain cases. Nevertheless, PRAME remains a valuable tool in the diagnostic and prognostic evaluation of melanocytic lesions, particularly when histological features are unclear or ambiguous. Further research is needed to refine its role in different melanoma subtypes and to explore its potential as a target for immunotherapy.
dc.formatapplication/pdf
dc.format.extent7
dc.identifier.doihttps://doi.org/10.14670/HH-18-944
dc.identifier.eissn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/171969
dc.languageeng
dc.relationSin financiacion externa a la Universidad
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.subjectImmunohistochemistry
dc.subjectBenign Nevi
dc.subjectMelanoma
dc.subject.odsNo relacionado con ningún objetivo de desarrollo sostenible
dc.titlePreferentially Expressed Antigen in Melanoma (PRAME) as a diagnostic and predictive marker in melanocytic tumors: An updated narrative review
dc.typeinfo:eu-repo/semantics/annotation
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Salzano-40-1889-1895-2025.pdf
Size:
872.91 KB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.37 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology, Vol.40, Nº12, (2025)